menu
    • menu

    Company profile for Mirum Pharmaceuticals

    NEW Drugs in Dev: 9
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of rare liver diseases. We are advancing our lead candidate, maralixibat for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mirum PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    950 Tower Lane, Suite 1050 Foster City, CA 94404
    Telephone
    Telephone
    650-667-4085
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://mirumpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mirum-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/mirumpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mirum Pharma Reveals Q1 2026 Financials And Business Update
    Mirum Pharma Reveals Q1 2026 Financials And Business Update

    06 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7275076

    FIRSTWORD PHARMA
    06 May 2026
    Share Share
    Mirum's rare liver Disease Drug Meets Main Goal in Mid-Stage
    Mirum's rare liver Disease Drug Meets Main Goal in Mid-Stage

    04 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/mirums-rare-liver-disease-drug-meets-main-goal-mid-stage-study-2026-05-04/

    REUTERS
    04 May 2026
    Share Share
    Mirum's Brelovitug Meets Primary Endpoint in Hep Delta Trial
    Mirum's Brelovitug Meets Primary Endpoint in Hep Delta Trial

    27 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7211233

    FIRSTWORD PHARMA
    27 Apr 2026
    Share Share
    Mirum Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
    Mirum Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    13 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260413572080/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    13 Apr 2026
    Share Share
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq

    12 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260312816557/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSSINESSWIRE
    12 Mar 2026
    Share Share
    Mirum Pharmaceuticals Provides AZURE Clinical Program Update
    Mirum Pharmaceuticals Provides AZURE Clinical Program Update

    05 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260305481077/en/Mirum-Pharmaceuticals-Provides-AZURE-Clinical-Program-Update-for-brelovitug-in-Chronic-Hepatitis-Delta-Virus

    BUSINESSWIRE
    05 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search